Research
Hormonal
Previous GLP-1 analogue CVOTs (albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide) demonstrate a reduction in major adverse cardiac events (MACE) and renal composite outcomes in people with Type 2 Diabetes.
If you have Type 2 Diabetes and heart disease or high risk, GLP-1 analogues (like semaglutide, liraglutide, etc.) are proven to reduce heart attacks, strokes, and cardiovascular death, in addition to lowering blood sugar.
StrongSupportsHIGH confidence
Cardiovascular outcome trials (CVOTs) evaluating glucagon-like peptide-1 (GLP-1) analogues have previously observed significant improvements in major adverse cardiac events in people with type 2 diabetes (T2D).
Why this rating
Based on multiple large-scale RCTs (CVOTs) with consistent findings.
Source
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
David M. Williams et al. · Diabetes Therapy · 2020
narrative_reviewCited 17×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →